Introduction
============

Increasing evidence shows that type 2 diabetes mellitus is associated with neurodegeneration and cerebral vascular disease ([@B5]). The presence of diabetes is a significant risk factor for the incidence of Alzheimer's disease (AD) and vascular dementia (VaD) in the elderly ([@B31]). Although the mechanism underlying its relationship with these phenomena is not fully understood, clinical features such as cognitive deficits, large- and small-vessel disease, cerebral atrophy, hypometabolism, and impaired insulin activation in the brain, overlap between type 2 diabetes and AD ([@B5]).

White matter hyperintensity (WMH), one of the cerebral small vessel diseases, presents as hyperintense areas on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images and as isointense or hypointense areas on T1-weighted images on magnetic resonance (MR) imaging. WMH is a common finding in the aging brain and plays pivotal roles in several geriatric syndromes, including cognitive impairment, gait disturbances and functional decline of the elderly ([@B4]; [@B29], [@B28]; [@B41]; [@B40]). Thus, preventive strategies capable of delaying WMH progression should be identified to successfully manage older people with diabetes.

Currently, age and hypertension are recognized as consistent risk factors for WMH ([@B41]). However, whether diabetes is independently associated with WMH has not been clarified. Several studies have reported that WMH volume is increased in patients with diabetes compared with non-diabetic subjects ([@B26]; [@B32]); however, other studies did not observe this finding ([@B13]; [@B24]). Some studies have focused on the association between HbA1c or fasting plasma glucose levels and WMH; however, the results of these studies were inconsistent ([@B8]; [@B12]; [@B15]; [@B32]; [@B36]). More recently, an association between fluctuations in HbA1c levels and WMH was reported in diabetes patients who carry the apolipoprotein E4 allele ([@B20]), which is a strong genetic risk factor for AD. Additionally, apolipoprotein E4 carriers who are elderly and have diabetes or higher HbA1c levels exhibited greater WMH progression than other individuals ([@B10]). These findings suggest that patients with diabetes who have experienced AD-related pathological changes in the brain may be more susceptible to metabolic stress than other patients.

Several imaging studies have reported that glucose alterations are associated with regional brain changes and dysfunctions. Diabetes patients with higher HbA1c levels exhibit regional brain atrophy, including as affected by the AD signature ([@B36]), and high insulin resistance was significantly associated with lower cerebral perfusion in frontal and temporal regions ([@B18]). However, regarding hypoglycemia, it remains controversial whether a hypoglycemic event is associated with brain dysfunction. Patients with symptomatic severe hypoglycemia exhibit similar patterns of brain atrophy and white matter abnormalities as those without a hypoglycemic episode ([@B45]). Conversely, another study reported that patients with prolonged hypoglycemic episodes show signal abnormalities in temporal and occipital lobes ([@B7]). Importantly, hypoglycemic episodes in older diabetes patients are unlikely to be reported due to mild or absent symptoms ([@B1]). Thus, to investigate the effects of hypoglycemia on brain abnormalities in elderly patients with diabetes, it is necessary to carefully investigate mild hypoglycemia that does not appear as a typical symptom and is not reported by patients.

To the best of our knowledge, no studies have examined differences in the effects of glucose alteration on brain abnormalities in diabetic patients with and without cognitive decline. The aim of the present study was to clarify the effects of glucose alteration on regional WMH and brain atrophy in older type 2 diabetes patients who have a diagnosis of AD or normal cognition (NC). In particular, we focused on the effects of hypoglycemia, postprandial hyperglycemia, and glucose fluctuations on regional WMH and brain atrophy among these patients. We measured daily glucose profiles using self-monitored blood glucose (SMBG) and also measured HbA1c levels. We hypothesized that abnormal glucose profiles in diabetes patients with AD are more likely to be associated with brain structural changes compared with NC patients.

Materials and Methods {#s1}
=====================

Participants
------------

This study was approved by the Ethics Review Board of Japan's National Center for Geriatrics and Gerontology (NCGG). All candidate subjects and their caregivers provided written informed consent to participate in the study prior to enrolling. We included 57 outpatients (AD: *n* = 23; NC: *n* = 34) who visited our hospital from 2014 to 2015 in the study. The diagnosis of probable or possible AD was based on the findings of the National Institute on Aging/Alzheimer's Association workgroups on the diagnostic guidelines for Alzheimer's disease ([@B21]). The following patients were included in the study: (a) outpatients with type 2 diabetes who were treated with antidiabetic agents, (b) patients aged 65 years or older, (c) patients living at their houses, (d) patients with a Mini-Mental State Examination (MMSE) score ≥ 10 for AD and (e) patients with family members or caregivers who assist with SMBG. The following patients were excluded from the study: (a) patients with type 1 diabetes, (b) patients with cortical lesions on MR imaging, (c) patients with neurological disorders other than AD and (d) patients with severe conditions, such as cardiac failure, renal disorder, or liver dysfunction.

Assessment of Clinical Parameters and Diabetic Complications
------------------------------------------------------------

The clinical data and blood samples used in this study were distributed from the NCGG Biobank, which collects and stores biological material and associated clinical information for biomedical research. Information regarding patient diagnoses, clinical information and medications was obtained from patient clinical charts. Global cognitive function was assessed by the MMSE ([@B14]).

The incidence of diabetic complications was determined based on the rates at which neuropathy, retinopathy and nephropathy co-existed with diabetes ([@B4]; [@B34]). Diabetic neuropathy was defined as either the loss of the Achilles tendon reflex or the presence neuropathic symptoms, such as paresthesia. Diabetic retinopathy was assessed by fundoscopy of dilated pupils, which was performed by experienced ophthalmologists. Diabetic nephropathy was assessed by measurements of the urinary albumin-to-creatinine ratio (ACR) and urinary protein concentrations, and nephropathy was defined as an ACR \> 300 μg/mg or a urinary protein concentration \> 30 mg/dL. The following biochemical indices were assessed in the study: HbA1c, triglycerides, total cholesterol, high-density cholesterol, low-density cholesterol, the estimated glomerular filtration rate, albumin and urinary albumin. HbA1c levels are expressed in National Glycohemoglobin Standardization Program units.

Daily glycemic levels were evaluated using SMBG (MS-FR201B; Terumo Corp., Tokyo, Japan) and were measured at 5 time points per day (5 AM, before breakfast, 2 h after breakfast, before lunch, and before dinner) on 8 separate days during a 2-month period. A previous study using continuous glucose monitoring (CGM) showed that glucose levels usually nadir early in the morning and before each meal and that postprandial glucose levels were likely to peak at 2 h after breakfast in patients with type 2 diabetes ([@B22]); therefore, we measured blood glucose levels at these time points. When patients with AD used SMBG, their families assisted with the measurements. Hypoglycemia was defined as a glucose level ≤ 70 mg/dL ([@B44]), and the presence or absence of hypoglycemic symptoms was reported at every SMBG measuring point. Glycemic fluctuations were calculated as diurnal ranges from minimum glucose levels to maximum glucose levels.

Evaluation of WMH and Brain Atrophy
-----------------------------------

All participants underwent T1- and T2-weighted and FLAIR MR imaging with 1.5T MR scanners (Siemens Avanto, Munich, Germany; or Philips Ingenia, Eindhoven, The Netherlands). WMH and brain atrophy were analyzed by an automatic segmentation application (SNIPER, Software for Neuro-Image Processing in Experimental Research: Department of Radiology, Leiden University Medical Center, The Netherlands) ([@B3]). WMH was evaluated in the frontal, temporal, occipital and parietal lobes. Global brain atrophy was calculated as the parenchyma (PAR) volume, which is determined by subtracting the cerebrospinal fluid volume from the intracranial (IC) volume. The PAR volume corresponds to the sum of the total gray and white matter volumes. WMH and brain atrophy parameters were divided by the IC volume to adjust for the size of each patient's brain. Further details regarding the MR scanning protocol and the automatic segmentation application are provided elsewhere ([@B3]; [@B30]).

To avoid misclassification of WMH in SNIPER, WMH segmentation was replicated using Lesion Segmentation Tool (LST) in Statistical Parametric Mapping 12 ([@B35]). LST is an automated segmentation approach for quantifying whole-brain WMH volume, and shows high agreement with manual tracing of WMH in FLAIR images ([@B35]).

Statistical Analysis
--------------------

All analyses were performed using the Japanese version of SPSS for Windows version 22.0 (IBM Corp., Armonk, NY, United States). Differences between the clinical profiles of the AD and NC groups were examined using the *t*-test (for parametric variables), Mann--Whitney *U* test (for non-parametric variables), and chi-squared test or Fisher's exact test (for categorical variables). To assess the association between each daily glucose index and WMH and brain atrophy, we performed multiple regression analysis. The dependent variables were WMH and brain atrophy, and the independent variables were the daily glucose indices. To identify the independent risk factors for WMH and brain atrophy, we performed multiple regression analysis with step-wise methods. Daily glucose indices that were in association in the previous analysis (*p* \< 0.10) were entered into this analysis as independent variables. Age, hypertension and HbA1c were entered into the analysis as adjustment variables for WMH, and age and HbA1c were entered into the analysis as possible confounders for brain atrophy. Statistical significance was set at *p* \< 0.05.

Results
=======

Clinical Features of the Study Participants
-------------------------------------------

The clinical profiles of the study participants are shown in **Table [1](#T1){ref-type="table"}**. The mean (±SD) age was 75.6 ± 5.8 years in the AD group and 74.1 ± 4.6 years in the NC group, respectively. The MMSE score was significantly lower in the AD group than in the NC group. There were no significant differences in the rates of diabetic comorbidities and antidiabetic agent use between the two groups. Although average HbA1c and serum triglyceride levels were higher in the AD group than NC group, the levels of the other metabolic and nutritional markers analyzed herein did not differ between the two groups. These results indicate that the diabetes statuses of the AD and NC groups were largely comparable.

###### 

Clinical characteristics of the study participants (*n* = 57).

                                              AD (*n* = 23)           NC (*n* = 34)           *p*-value
  ------------------------------------------- ----------------------- ----------------------- -----------
  Age, years                                  75.6 (5.8)              74.1 (4.6)              0.289
  Male, n (%)                                 12 (52.2)               19 (55.9)               0.783
  Education, years                            11.3 (2.6)              11.5 (2.6)              0.519
  Duration of diabetes, years                 14.2 (10.4)             14.4 (9.3)              0.665
  Mini-Mental State Examination               20.4 (4.5)              27.4 (2.1)              \<0.001
  Body mass index, kg/m^2^                    23.5 (2.8)              24.2 (2.7)              0.347
  History of hypertension, n (%)              17 (73.9)               27 (79.4)               0.627
  History of coronary artery disease, n (%)   5 (21.7)                8 (23.5)                0.874
  Comorbidities of diabetes, n (%)                                                            
  Diabetic neuropathy                         16 (69.6)               21 (61.8)               0.545
  Diabetic retinopathy                        3 (13.0)                11 (32.4)               0.097
  Diabetic nephropathy                        9 (39.1)                9 (26.5)                0.313
  Antidiabetic agents, n (%)                                                                  
  Biguanide                                   6 (26.1)                10 (29.4)               0.784
  Thiazolidine                                5 (21.7)                2 (5.9)                 0.106
  DPP4 inhibitor                              17 (73.9)               23 (67.6)               0.612
  Sulfonylurea                                12 (52.2)               20 (58.8)               0.620
  Insulin secretion promoter                  2 (8.7)                 0 (0.0)                 0.159
  α-glucosidase inhibitor                     2 (8.7)                 9 (26.5)                0.170
  Insulin                                     5 (21.7)                6 (17.6)                0.742
  GLP-1 receptor agonists                     1 (4.3)                 1 (2.9)                 1.000
  Biochemical examination                                                                     
  HbA1c, %                                    7.4 (0.7)               7.1 (0.5)               0.044
  Triglycerides, mg/dL                        170.0 (81.1)            120.0 (58.3)            0.019
  Total cholesterol, mg/dL                    188.1 (43.3)            190.7 (42.8)            0.968
  HDL cholesterol, mg/dL                      52.4 (15.4)             55.6 (13.6)             0.425
  LDL cholesterol, mg/dL                      102.9 (37.9)            110.4 (36.2)            0.384
  eGFR, mL/min/1.73 m^2^                      65.2 (17.9)             62.7 (18.6)             0.623
  Albumin, g/dL                               4.2 (0.4)               4.4 (0.3)               0.105
  UACR, mg/gCr                                116.6 (213.9)           158.1 (348.2)           0.362
  Self-monitoring of blood glucose                                                            
  5 AM, mg/dL                                 112.5 (21.8)            120.1 (25.1)            0.337
  Before breakfast, mg/dL                     119.4 (21.2)            126.9 (23.3)            0.222
  2 h after breakfast, mg/dL                  183.2 (38.7)            178.6 (28.8)            0.833
  Before lunch, mg/dL                         139.4 (44.3)            118.2 (26.9)            0.053
  Before dinner, mg/dL                        139.1 (37.6)            133.9 (19.8)            0.814
  Fluctuation, mg/dL                          96.8 (32.7)             86.9 (24.8)             0.200
  Frequency of hypoglycemia^∗^                0.61 (1.6)              0.62 (1.1)              0.579
  MR imaging                                                                                  
  IC, mL                                      1458.2 (130.4)          1400.9 (141.1)          0.127
  PAR, mL, % of IC                            1113.7 (125.4), 76.3%   1117.8 (140.2), 79.7%   0.003
  WMH, mL, % of IC                            16.6 (13.0), 1.14%      11.0 (12.8), 0.79%      0.029
  Frontal lobe, mL, % of IC                   10.9 (9.4), 0.76%       6.1 (6.1), 0.44%        0.010
  Temporal lobe, mL, % of IC                  1.0 (1.2), 0.07%        0.9 (1.5), 0.06%        0.216
  Occipital lobe, mL, % of IC                 0.5 (0.4), 0.03%        0.4 (0.5), 0.03%        0.162
  Parietal lobe, mL, % of IC                  4.1 (3.9), 0.28%        3.5 (5.2), 0.26%        0.126
  Periventricular area, mL, % of IC           15.4 (13.1), 1.06%      10.3 (12.7), 0.74%      0.029
  Deep subcortical areas, mL, % of IC         1.2 (1.3), 0.08%        0.7 (0.9), 0.05%        0.216

Data are presented as the mean (standard deviation) or as numbers and percentages unless otherwise indicated.

∗

Indicated per-patient averages at the measuring points during the study period. AD, Alzheimer's disease; DPP4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HDL cholesterol, high-density lipoprotein cholesterol; IC, intracranial; LDL, low-density lipoprotein cholesterol; MR, magnetic resonance; NC, normal cognition; PAR, parenchyma; UACR, urine albumin-to-creatinine ratio; WMH, white matter hyperintensity.

The average blood glucose levels at the 5 SMBG measuring points used during each of the 8 days are shown in **Table [1](#T1){ref-type="table"}**. Mean pre-lunch glucose levels tended to be higher in the AD group than NC group, but there were no significant differences in any daily glucose indices between the two groups. Hypoglycemia (blood glucose range: 43 mg/dL -- 70 mg/dL) was observed at 14 measuring points (1.5% of all measuring points) in the AD group and 21 measuring points (blood glucose range: 45 mg/dL -- 70 mg/dL, 1.5% of all measuring points) in the NC group. Severe hypoglycemic symptoms and events were not reported in this study. Typical hypoglycemic symptoms, such as palpitations and hand tremors, were observed in one individual in the NC group whose glucose level was 45 mg/dL. Hypoglycemia-related symptoms, including nausea, dizziness, light-headedness, blurred vision and fatigue, were reported at 4 measuring points (0.4%) in the AD group and 3 measuring points (0.2%) in the NC group during the 2-month period.

Total WMH volume of all subjects was 13.3 ± 13.1 ml in SNIPER and 12.7 ± 11.2 ml in LST. Total WMH volume in each application program showed high correlation (**Figure [1](#F1){ref-type="fig"}**), suggesting that the method of measurement used for SNIPER was reliable. MR imaging evaluated by SNIPER showed that the AD group had a significantly greater WMH volume than the NC group, particularly in the frontal lobe. In addition, patients in the AD group had more severe brain atrophy than patients in the NC group. Because the deep white matter hyperintensity (DWMH) volume was markedly smaller than the periventricular hyperintensity (PVH) volume in both patient groups, we combined the PVH and DWMH volumes into the WMH volume in all brain regions in subsequent analyses.

![Distribution of total WMH. Scatterplot showing distribution of total WMH (ml) in SNIPER and LST. Black dots and the solid line represent AD. White dots and the dashed line represent NC. AD, Alzheimer's disease; LST, Lesion Segmentation Tool; NC, normal cognition; SNIPER, Software for Neuro-Image Processing in Experimental Research; WMH, white matter hyperintensity.](fnagi-10-00273-g001){#F1}

Associations Between Glucose Indices and WMH and Brain Atrophy
--------------------------------------------------------------

The relationships between several glucose indices and MR imaging parameters are shown in **Table [2](#T2){ref-type="table"}**. Because age and hypertension are consistent risk factors for WMH, these variables were entered into the analysis as adjustment variables for WMH, while age was entered as an adjustment variable for brain atrophy. Glucose levels at 2 h after breakfast and daily fluctuations in blood glucose levels were associated with WMH in the frontal lobe in the AD group. Glucose levels at 2 h after breakfast and fluctuations in glucose levels tended to be inversely associated with PAR volume. The frequency of hypoglycemia (glucose level ≤ 70 mg/dL) was not correlated with WMH or brain atrophy. The effect of mild hypoglycemia (glucose level ≤ 80 mg/dL or ≤90 mg/dL) on brain structural changes was also examined in this study. Mild hypoglycemia defined as a glucose level ≤ 80 mg/dL was observed at 5.1% of all SMBG measuring points, and mild hypoglycemia defined as a low glucose level ≤ 90 mg/dL was observed at 14.0% of all SMBG measuring points in the AD group. However, there were no associations between the frequency of mild hypoglycemia and MR imaging parameters.

###### 

Associations between glucose indices and WMH and brain atrophy.

                              White matter hyperintensity   PAR                                                                                  
  --------------------------- ----------------------------- ------- -------- ------- -------- ------- -------- ------- -------- ------- -------- -------
  **AD subjects**                                                                                                                                
  5 AM                        −0.020                        0.929   −0.036   0.877   −0.004   0.987   0.061    0.771   0.014    0.953   −0.357   0.099
  Before breakfast            0.098                         0.670   0.095    0.680   0.029    0.899   0.036    0.864   0.076    0.744   −0.223   0.313
  2 h after breakfast         0.397                         0.099   0.521    0.027   −0.131   0.596   −0.112   0.626   0.055    0.827   −0.438   0.061
  Before lunch                0.074                         0.776   0.088    0.737   0.089    0.731   0.208    0.384   −0.032   0.903   −0.396   0.109
  Before dinner               0.243                         0.289   0.203    0.381   0.145    0.528   0.377    0.067   0.239    0.303   −0.326   0.139
  Fluctuation                 0.385                         0.086   0.502    0.022   −0.167   0.468   0.000    0.999   0.068    0.774   −0.419   0.051
  Frequency of hypoglycemia   0.042                         0.863   0.071    0.773   −0.096   0.691   −0.051   0.822   −0.008   0.974   −0.218   0.346
  **NC subjects**                                                                                                                                
  5 AM                        −0.124                        0.510   −0.091   0.633   −0.177   0.342   −0.109   0.548   −0.136   0.474   −0.160   0.328
  Before breakfast            −0.015                        0.939   0.010    0.958   −0.068   0.724   −0.097   0.605   −0.019   0.924   −0.155   0.347
  2 h after breakfast         −0.217                        0.223   −0.230   0.197   −0.142   0.426   −0.074   0.667   −0.214   0.234   −0.470   0.001
  Before lunch                −0.098                        0.588   −0.069   0.705   −0.135   0.453   −0.193   0.266   −0.101   0.581   −0.095   0.546
  Before dinner               −0.092                        0.610   −0.070   0.700   −0.107   0.547   −0.033   0.848   −0.107   0.556   −0.087   0.574
  Fluctuation                 −0.161                        0.370   −0.182   0.311   −0.053   0.768   −0.052   0.766   −0.161   0.375   −0.393   0.007
  Frequency of hypoglycemia   0.229                         0.222   0.146    0.443   0.369    0.042   0.162    0.371   0.270    0.152   0.011    0.942

Multiple regression analysis was performed with the forced-entry method. The dependent variables were the MR imaging parameters. The independent variables were the daily glucose indices. Age and hypertension were entered into the analysis as classical confounders for WMH. Age was entered into the analysis as a classical confounder for brain atrophy. AD, Alzheimer's disease; NC, normal cognition; PAR, parenchyma.

The average blood glucose level at each time point was not associated with WMH in the NC group. Glucose levels at 2 h after breakfast and fluctuations in blood glucose levels were associated with brain atrophy. The frequency of hypoglycemia (glucose level ≤ 70 mg/dL) was weakly related to WMH in the temporal lobe. Mild hypoglycemia defined as a low glucose ≤ 80 mg/dL was observed at 4.3% of all SMBG measuring points, and mild hypoglycemia defined as a low glucose ≤ 90 mg/dL was observed at 10.1% of all SMBG measuring points in subjects with NC. However, there were no associations between the frequency of mild hypoglycemia and MR imaging parameters.

Independent Risk Factors for Regional WMH and Brain Atrophy
-----------------------------------------------------------

To determine whether blood glucose was independently associated with regional WMH and brain atrophy, we conducted multiple regression using a step-wise method (**Table [3](#T3){ref-type="table"}**). When WMH was entered as a dependent variable, age, hypertension, HbA1c and daily glucose indices (*p* \< 0.10 in **Table [2](#T2){ref-type="table"}**) were entered as independent variables. When brain atrophy was entered as a dependent variable, age, HbA1c and daily glucose indices (*p* \< 0.10 in **Table [2](#T2){ref-type="table"}**) were entered as independent variables. The results showed that elevated blood glucose levels at 2 h after breakfast were independently associated with frontal WMH in the AD group. Blood glucose levels at 2 h after breakfast were inversely associated with PAR volume. We could not identify the independent risk factors for WMH in the temporal lobe in the NC group. Age and blood glucose levels at 2 h after breakfast were independently associated with global brain atrophy in the NC group.

###### 

Independent risk factors for regional WMH and brain atrophy.

                         Factors               β        95% CI             *p*-value
  ---------------------- --------------------- -------- ------------------ -----------
  **AD subjects**                                                          
  WMH in frontal lobe    2 h after breakfast   0.489    (0.002; 0.017)     0.018
  PAR                    2 h after breakfast   −0.442   (−0.085; −0.003)   0.035
  **NC subjects**                                                          
  WMH in temporal lobe   N/A                            N/A                
  PAR                    2 h after breakfast   −0.470   (−0.107; −0.030)   0.001
                         Age                   −0.460   (−0.665; −0.179)   0.001

Multiple regression analysis with the step-wise method. The dependent variables were the MR imaging parameters. The independent variables were the daily glucose indices (

p

\< 0.10 in the previous analysis). Age, hypertension and HbA1c were entered into the analysis as classical confounders for WMH. Age and HbA1c were entered into the analysis as classical confounders for brain atrophy. AD, Alzheimer's disease; NC, normal cognition; PAR, parenchyma; WMH, white matter hyperintensity.

Discussion
==========

The present study revealed that postprandial hyperglycemia was independently associated with frontal WMH in patients with AD. In addition, postprandial hyperglycemia was significantly associated with brain atrophy, regardless of whether cognitive decline was present. Altogether, our findings indicate that postprandial hyperglycemia is associated with WMH in only AD patients, which suggests that AD patients are more susceptible to postprandial hyperglycemia associated with WMH.

To the best of our knowledge, this study was the first to clarify the effects of postprandial hyperglycemia on regional WMH and brain atrophy. In the current study, glucose fluctuations were calculated as diurnal ranges between peaks and nadirs. Glucose levels usually peaked at 2 h after breakfast, and nadirs were observed early in the morning and during inter-prandial periods ([@B22]). A large prospective cohort study revealed that postprandial glucose but not fasting glucose was independently associated with AD and VaD ([@B31]). This study has shown that diurnal fluctuations in blood glucose are a risk factor for neurodegeneration and cerebrovascular damage. Several studies have obtained conflicting results regarding the associations between glucose indices and WMH. One study found that higher HbA1c levels were associated with WMH ([@B36]), while other studies did not find such an association ([@B12]; [@B32]). These controversies may result from a failure to capture daily glucose variability. HbA1c reflects the average glucose level over the past 4--8 weeks; however, patients with similar HbA1c levels may experience fluctuations in their glucose levels. Our observations implied that measurements of daily glucose variability may better capture the contributions of abnormal glucose metabolism to WMH. Physicians should manage glucose fluctuations carefully, particularly to avoid rapid increases in postprandial glucose levels.

The relationship between postprandial hyperglycemia and WMH was found to be consistent after adjustment for classical confounders, including age and hypertension. Hyperglycemia increases the formation of advanced glycation end-products, which induces oxidative stress and inflammation and exacerbates brain microvascular endothelial function ([@B39]). However, glucose variability also independently contributes to the development of microvascular complications ([@B38]). Moreover, acute glucose fluctuations are a greater trigger of oxidative stress than sustained hyperglycemia ([@B23]). Unfortunately, no data pertaining to oxidative stress levels were available in this study. However, glucose fluctuations and postprandial glucose levels are associated with oxidative stress levels ([@B9]; [@B23]). Increased oxidative stress is observed in the diabetic brain ([@B33]), and the brain is vulnerable to oxidative damage because it consumes high levels of oxygen and has high lipid content and weak antioxidant defenses ([@B25]). Furthermore, the brain tissue of patients with AD is exposed to oxidative stress during the course of the disease ([@B16]). Therefore, our observations suggest that postprandial hyperglycemia may induce additional oxidative stress in the AD brain, which is already under increased oxidative stress, and this might be a cause of WMH progression in AD.

Interestingly, we noted an association of postprandial hyperglycemia with WMH in the frontal lobe. Previous study indicated that diabetes patients have greater WMH in the frontal lobe, and WMH volume is associated with reduced cerebral blood flow velocities in the middle cerebral arteries ([@B26]). More recently, insulin resistance in association with lower cerebral perfusion in the frontal and temporal regions has been proposed ([@B18]). Diabetes induces endothelial dysfunction and permeability of the blood-brain barrier, which may affect the regional blood flow and metabolism of the brain ([@B26]; [@B19]). In line with current literature, our observation suggests that abnormal glucose metabolism might be sensitively associated with cerebral circulation and metabolism, mainly in the frontal lobe.

The association between postprandial hyperglycemia and frontal WMH was observed only in AD. In the current study, patients with AD had a larger global WMH volume, which corresponded to grade 2--3 on the Fazekas scale, than patients with NC, whose WMH volume corresponded to grade 1 ([@B27]). WMH volume increased markedly with aging, particularly in the frontal lobe in patients aged 75 years and over who were in the AD/aMCI cohort ([@B30]). The pathogenesis of WMH is most likely driven by ischemia resulting from hypertensive small vessel disease, but amyloid angiopathy may also be another underlying cause of extensive WMH ([@B41]). More recently, carriage of the apolipoprotein E4 genotype was reported to affect the relationship between glucose alterations and WMH ([@B20]; [@B10]). Thus, patients with AD have a variety of pathologies, including small vessel disease, and may be more susceptible to the effects of glucose exacerbation on WMH progression. There was no association between glucose indices and WMH in patients with NC. However, a recent study used the glycoalbumin/HbA1c ratio, a marker of glucose variability, to reveal a significant relationship between these glucose indices and WMH in subjects with NC ([@B40]). Additional studies are needed to confirm this association in large populations of elderly patients with diabetes.

In the current study, we noted a weak association between hypoglycemia and temporal WMH in patients with NC; however, whether the two variables were independently associated with each other was less clear. Furthermore, we could not find such an association in patients with AD, who are considered susceptible to glucose metabolism exacerbations. This result may be explained by the study participants' blood glucose levels being relatively well controlled and severe hypoglycemic events being rarely observed during the study period. Therefore, it was difficult to evaluate the effects of hypoglycemia diagnosed based on the presence or absence of hypoglycemic symptoms on brain abnormalities. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial found no significant association between symptomatic severe hypoglycemia and abnormal white matter volume ([@B45]). We further addressed concerns about repeated mild hypoglycemia in associated with brain abnormalities; however, the results indicated that mild hypoglycemia is not associated with WMH or brain atrophy.

Accumulating evidence indicates that diabetes is associated with global and regional brain atrophy ([@B13]; [@B24]; [@B17]; [@B32]; [@B36]). The results of our study extend current observations and clearly demonstrate that postprandial hyperglycemia is independently associated with global brain atrophy. A previous study indicated that the regional brain atrophy patterns of elderly patients with diabetes resemble those of patients with AD ([@B24]; [@B36]). Regarding its regional distribution, brain atrophy was found in the frontal, temporal, and parietal lobes and the hippocampus, and cortical gray matter loss was more prominent in the left hemisphere than in the right hemisphere ([@B24]; [@B36]). Furthermore, insulin resistance is significantly associated with AD-induced progressive regional atrophy ([@B43]), and higher glucose levels are significantly associated with an increased risk of dementia, including AD ([@B11]). Because the association between postprandial hyperglycemia and global brain atrophy was also seen in subjects with NC, we can conclude that accurate glucose control is necessary to prevent brain atrophy.

The present study has several limitations. First, the current study had a cross-sectional design. Therefore, our findings regarding the causal relationship between postprandial hyperglycemia and WMH and brain atrophy should be considered carefully. Second, we examined brain atrophy by parenchymal volume. WMH are associated with white matter atrophy and cortical thinning ([@B42]). Importantly, WMH in AD patients involves both vascular changes and neurodegenerative mechanisms ([@B41]). Thus, it is necessary to separately measure gray and white matter volume to assess the burden of WMH in AD brain. Consequently, it may be more appropriate to estimate regional brain atrophy using voxel-based morphometry by statistical parametric mapping ([@B2]). Moreover, although we used a standard 1.5T scanner to examine WMH, high-field MR scanners have greater sensitivity for detecting small WMH ([@B37]; [@B46]). Accordingly, future research should use high-field MR scanners to detect subtle WMH. Third, the daily glucose indices measured in this study are not indicators of long-term glucose profiles. However, we investigated daily glucose indices during 8 separate days over a 2-month period to avoid time point deviation in glucose values; thus, our findings may reflect the quality of glucose management over this period. Although this study used SMBG to evaluate glucose levels, CGM might more accurately measure glucose profiles ([@B6]). Nonetheless, it is difficult to continuously monitor glucose levels using CGM in patients with AD. Therefore, the use of SMBG might be suitable in studies that include patients with cognitive decline. Finally, the number of study participants was relatively small. However, our sample size was largely comparable to that of a previous study that found that patients with AD-related pathological changes are susceptible to glucose changes associated with the progression of WMH ([@B20]). Additional longitudinal studies with a large sample size may provide further evidence to confirm our findings.

Conclusion
==========

In conclusion, postprandial hyperglycemia was found to be independently associated with frontal WMH in patients with AD. In addition, postprandial hyperglycemia is significantly associated with brain atrophy, regardless of the presence of cognitive decline. Thus, our findings suggest that postprandial hyperglycemia is associated with WMH in AD patients but not NC patients, which suggests that AD patients are more susceptible to postprandial hyperglycemia associated with WMH. Our current study provides preliminary results but further longitudinal studies are needed to clarify the effect of glucose management on WMH progression. This study involves a small sample size based on a single dataset, thus confirmation in future longitudinal studies with a larger cohort is required.

Author Contributions
====================

NO analyzed the data and wrote the manuscript. TS designed the study, analyzed the data, performed the data acquisition, and wrote the manuscript. SK, TT, HT, SS, HM, AS, and MKo performed the data acquisition and contributed to the discussion. SN provided control resources. KT, HU, and MKu reviewed and edited the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This study was supported by a grant from the Research Funding for Longevity Sciences (25-6, 27-21) from the NCGG.

We thank the NCGG Biobank for providing quality control of the clinical data and blood samples. We are also grateful to Norio Sugimoto (Innovation Center for Clinical Research, NCGG) for providing technical assistance for the statistical analysis.

[^1]: Edited by: Roberto Monastero, Università degli Studi di Palermo, Italy

[^2]: Reviewed by: Carme Junque, University of Barcelona, Spain; Yong Liu, Institute of Automation (CAS), China
